Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04430595 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Multi-4SCAR-T Therapy Targeting Breast Cancer

StatusNot Yet Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Jun 1, 2026 to Jun 1, 2027
    • Trial status changed: Recruiting → Not Yet Recruiting
    • Study description expanded, about 66 words
    • Site details revised
    v3
  2. Primary completion date: May 31, 2023 to Dec 31, 2029v2 Show 4 more changesShow less
    • Start date changed from estimate of Jun 1, 2020 to Jun 1, 2026
    • Study completion date: Dec 31, 2023 to Dec 31, 2030
    • Study site revised
    • Collaborators shortened, about 8 words
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to assess the feasibility, safety and efficacy of multiple 4th generation CAR-T cells targeting Her2, GD2, and CD44v6 surface antigen in breast cancer. Another goal of the study is to learn more about the activities of the multi-CAR T cells and their persistency in the patients.
Trial Details
NCT Number NCT04430595
Lead Sponsor Shenzhen Geno-Immune Medical Institute
Conditions
(from sponsor)		 Breast Cancer
Related terms Breast Neoplasms
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov